Metabolically active visceral fat linked to aggressive endometrial cancer, new study reveals

Published Date: 05 Oct 2025

High metabolic activity of visceral fat may be associated with more aggressive endometrial cancer, new research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25) has shown.

Read Full News

Latest News

Coffee and the Gut: What’s Brewing in the Microbiome?

Emerging evidence suggests coffee influences gut microbiota through bioactive compounds beyond caffeine, with potential effects on digestive and metabolic health.

GLP-1s for Addiction: Are We There Yet?

The same drugs that transformed obesity treatment are now being investigated for substance use disorders, fueling interest in a new approach to addiction treatment.

OTC Continuous Glucose Monitor Adds AI Features

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI coaching and other app-based features.

Analysis-Older Americans Left Out Of Costly GLP-1 Craze Expected to Flock to New Program

Millions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to...

Explainer-Who Qualifies for Medicare's New $50 Weight-loss Drug Program and What Are the Concerns?

Millions of Americans are expected to gain coverage for GLP-1 drugs for weight loss under a new U.S. pilot launching on Wednesday in its Medicare program for people aged 65...

Tirzepatide Weight Loss Greater in Women vs Men, Age No Link

In adults with overweight or obesity using tirzepatide for at least 12 months, women lost more weight, but age was not a predictor.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

Emerging evidence suggests coffee influences gut microbiota through bioactive compounds beyond caffeine, with potential effects on digestive and metabolic health.

The same drugs that transformed obesity treatment are now being investigated for substance use disorders, fueling interest in a new approach to addiction treatment.

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI coaching and other app-based features.

Millions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to...

Millions of Americans are expected to gain coverage for GLP-1 drugs for weight loss under a new U.S. pilot launching on Wednesday in its Medicare program for people aged 65...

In adults with overweight or obesity using tirzepatide for at least 12 months, women lost more weight, but age was not a predictor.

News All Time

When a Kid’s Bad Behavior Is Actually Hidden Sleep Disorder

In children, the effects of sleep problems may be even more pronounced than in adults because sleep is closely tied to growth, learning, and brain maturation.

Unapproved Retatrutide Use Challenges Clinicians

Non-FDA approved retatrutide is readily available to US consumers from multiple sources, leaving many clinicians grappling with how to manage patients taking the drug.

Imaging Predicts Therapy Failure in T2-T3 Glottic Cancers

Vertical anterior commissure involvement identified on preoperative imaging predicts poor outcomes in patients undergoing primary chemoradiotherapy for T2-T3 glottic tumours.

QOL After Weight-Loss Surgery Persists Despite Regain

In a prospective study, long-term improvements in QOL after metabolic and bariatric surgery are largely maintained in both patients experiencing weight regain of less than 30% and 30% or more.

Bariatric Surgery Outperforms Diet for Cancer Prevention

Metabolic/bariatric surgery is linked to a lower risk for multiple cancers in patients with severe obesity than dietary counseling, a large analysis shows.

Bone Agents Underused, and Declining, in Prostate Cancer

Many patients with metastatic castration-resistant prostate cancer are not receiving bone-modifying agents, despite guideline endorsement.

Novo's Top US Exec Wants More Insurance Coverage for Weight-loss Drugs

Denmark's Novo Nordisk, the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S. users of the medication and balance direct-to-consumer sales that have...

Two Studies Link GLP-1 Use to Lower Breast Cancer Risk

Two studies, including one involving more than 100,000 women, linked GLP-1 receptor agonists to reduced incidence of breast cancer.

Trump Pricing Policy Will Affect Obesity Drug Launch in Europe

Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of ⁠2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market.

GLP-1 QOL Benefits Greatest for Those With Obesity Plus T2D

Patients with co-occurring obesity and T2D have more favorable QOL outcomes on GLP-1s than those with either condition alone or multiple comorbidities.

China Approval for Eli Lilly GLP-1 Pill to Come as Soon as 2026, Executive Says

Eli Lilly's orforglipron type-2 diabetes and obesity pill could launch in China as soon ⁠as later this year, an executive at the U.S. drugmaker told Reuters, as rival Novo...

Mediterranean Diet May Reduce Postpartum Metabolic Risk

A Mediterranean-based nutritional intervention initiated at 8-12 gestational weeks is associated with a reduced risk for metabolic syndrome 6 years postpartum, a prospective follow-up study finds.

Urogenital Infections Tied to SGLT2 Therapy Discontinuation

Patients with type 2 diabetes who start SGLT2 inhibitors and then develop a urinary or genital tract infection are more likely to discontinue treatment than matched patients without an infection.

Fasting and Calorie Restriction Work via Different Pathways

In adults with obesity, both intermittent fasting and calorie restriction lead to significant weight loss but act through distinct behavioral pathways.

What GLP-1s Are Teaching Us About Compulsive Behavior

As GLP-1 research moves deeper into the brain, scientists are asking whether these drugs can help explain why some urges become so hard to resist.

Protein Source Key for Weight Loss After Menopause

Postmenopausal women are often encouraged to eat more protein, but a new study finds that protein source matters, with plant-based protein outperforming animal protein for weight loss.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot